Index to Volume 158

Author Index

Abbo, H., 1227
Abbott, M. A., 1158
Abdillahi, H., 209
Adan, A., 1139
Adrian, T., 804
Agius, G., 1235
Aguilar Luque, J., 653
Ahmed, F., 60
Ahmed, R., 232
Alam, N. H., 742
Albert, J., 866
Albert, M. J., 477
Alcid, D. V., 1135
Alexander, S. S., 1235
Alexander, W. J., 518
Alford, C. A., 109, 917
Anacker, R. L., 228
Anderson, E. L., 1261
Anderson, L. J., 804, 1112
Andres, N., 655
Andrews, C. A., 176
Andriole, V. T., 415
Ansaruzzaman, M., 372
Appleman, M. D., 1185
Appleman, M. E., 193
Arango-Jaramillo, S., 1120
Arcese, W., 647
Armstrong, J. A., 124
Arnheim, N., 1185
Arthur, R. R., 563
Arvilommi, H., 1011
Arvin, A. M., 109, 1245
Ashdown, L. R., 491
Ashley, R., 1227
Aso, S., 1296
Auckenthaler, R., 693
Augustine, N. H., 823
Aulitzky, W. E., 488
Austin, H., 518
Aweeka, F., 862
Ayoub, E. M., 965, 1092
Babiak, T., 884
Bach, N., 795
Bacher, J., 80
Bacon, A. E., 349
Baczko, K., 144
Badur, S., 666
Bagasra, O., 1084
Baguet, J.-P., 1400
Bakenhaster, K., 907
Baker, C. J., 471, 724
Baldassarri, L., 647
Ballou, L. R., 848
Bancroft, W. H., 876
Barnes, P. F., 366
Baroudy, B. M., 151
Barry, D. W., 503
Bartlett, J. G., 464
Bartlett, M. S., 1137
Bartos, L. C., 761
Baughn, R. E., 940
Bautista, S., 681
Baxby, D., 1038
Bayer, A. S., 355, 1003
Beatty, D. C., 193
Beaucaire, G., 646
Bell, L. M., 570
Belshe, R. B., 1261
Benach, J. L., 667
Bendheim, P. E., 1198
Beninger, P. R., 1396
Bennett, J. E., 407
Bennett, W. M., 13
Benson, C. A., 1132
Berardi, V. P., 748, 754
Berberich, H., 291, 301
Bergdoll, M. S., 1105
Berger, C., 654
Bergmann, K. F., 151
Bergstrom, R., 23
Bernstein, J. M., 205
Berryman, G. K., 501
Bester, J., 1329
Betts, R. F., 1209
Betz, T. G., 217
Beytout, D., 1400
Bhagavati, S., 1193
Bhan, M. K., 1117
Bhandari, N., 1117
Biggar, R. J., 1235
Billeter, M. A., 144
Binns, B., 510
Birch, C., 895
Bistowish, J. M., 1253
Blacklock, Z. M., 52
Blacklow, N. R., 182
Blanch, L., 496
Blaser, M. J., 983
Blattner, W. A., 1235
Blum, M. R., 489
Blundell, N., 1038
Bohnsack, J. F., 823
Boiteux, J.-P., 1400
Bolin, C. A., 246
Bolton, D. C., 1198
Borian, F. E., 570
Borrow, P., 186
Boswell, R. N., 193
Boue, F., 666
Bowden, R. A., 773
Boyle, M. D. P., 965
Bradley, D. W., 355
Brady, L. J., 965
Brady, L. M., 499
Breinig, M. K., 124
Brenneman, G., 719
Brew, B. J., 1079
Brey, R. L., 193
Britt, W., 917
Broggini, M., 1398
Brummett, R. E., 13
Brummitt, C. F., 423
Brunham, R. C., 510, 524, 661
Brüssow, H., 588
Budinsky, A., 660
Buescher, E. S., 1140
Buffone, G. J., 1177
Bugelski, P., 1065
Bugert, J., 898
Buller, M., 893
Burke, D. S., 876
Burke, J. P., 903
Burkhart, K., 719
Burns, B., 1261
Burns, J., 859
Burns, W. H., 596
Busch, M. P., 1088
Butler, T., 742
Byrne, B. C., 1158
Cairo, M. S., 1268
Calandra, T., 312
Campbell, G. H., 868
Campbell, J. R., 325
Campbell, P. A., 1309
Cantin, E. M., 1382
Caprioli, A., 647
Carlisle, J. T., 244
Carpenter, T., 7
Catlin, B. W., 529
Cattaneo, R., 144
Causey, D. M., 1185
Chadee, K., 398
Chai, C. Y., 633
Chakraborty, J., 60, 372
Chambers, H. F., 7
Chan, L. S., 366
Chandler, F. W., 480
Chang, R., 633
Chang, S. A., 633
Chang, Y. H., 633
Chanock, R. M., 1261
Chapelle, N., 1400
Charache, P., 563
Chatfield, S., 1329
Cheeks, J., 518
Chen, C. J., 633
Cherrington, J. M., 423
Chevallier, I., 89

Index to Volume 158

Author Index

Abbo, H., 1227
Abbott, M. A., 1158
Abdillahi, H., 209
Adan, A., 1139
Adrian, T., 804
Agius, G., 1235
Aguilar Luque, J., 653
Ahmed, F., 60
Ahmed, R., 232
Alam, N. H., 742
Albert, J., 866
Albert, M. J., 477
Alcid, D. V., 1135
Alexander, S. S., 1235
Alexander, W. J., 518
Alford, C. A., 109, 917
Anacker, R. L., 228
Anderson, E. L., 1261
Anderson, L. J., 804, 1112
Andres, N., 655
Andrews, C. A., 176
Andriole, V. T., 415
Ansaruzzaman, M., 372
Appleman, M. D., 1185
Appleman, M. E., 193
Arango-Jaramillo, S., 1120
Arcese, W., 647
Armstrong, J. A., 124
Arnheim, N., 1185
Arthur, R. R., 563
Arvilommi, H., 1011
Arvin, A. M., 109, 1245
Ashdown, L. R., 491
Ashley, R., 1227
Aso, S., 1296
Auckenthaler, R., 693
Augustine, N. H., 823
Aulitzky, W. E., 488
Austin, H., 518
Aweeka, F., 862
Ayoub, E. M., 965, 1092
Babiak, T., 884
Bach, N., 795
Bacher, J., 80
Bacon, A. E., 349
Baczko, K., 144
Badur, S., 666
Bagasra, O., 1084
Baguet, J.-P., 1400
Bakenhaster, K., 907
Baker, C. J., 471, 724
Baldassarri, L., 647
Ballou, L. R., 848
Bancroft, W. H., 876
Barnes, P. F., 366
Baroudy, B. M., 151
Barry, D. W., 503
Bartlett, J. G., 464
Bartlett, M. S., 1137
Bartos, L. C., 761
Baughn, R. E., 940
Bautista, S., 681
Baxby, D., 1038
Bayer, A. S., 355, 1003
Beatty, D. C., 193
Beaucaire, G., 646
Bell, L. M., 570
Belshe, R. B., 1261
Benach, J. L., 667
Bendheim, P. E., 1198
Beninger, P. R., 1396
Bennett, J. E., 407
Bennett, W. M., 13
Benson, C. A., 1132
Berardi, V. P., 748, 754
Berberich, H., 291, 301
Bergdoll, M. S., 1105
Berger, C., 654
Bergmann, K. F., 151
Bergstrom, R., 23
Bernstein, J. M., 205
Berryman, G. K., 501
Bester, J., 1329
Betts, R. F., 1209
Betz, T. G., 217
Beytout, D., 1400
Bhagavati, S., 1193
Bhan, M. K., 1117
Bhandari, N., 1117
Biggar, R. J., 1235
Billeter, M. A., 144
Binns, B., 510
Birch, C., 895
Bistowish, J. M., 1253
Blacklock, Z. M., 52
Blacklow, N. R., 182
Blanch, L., 496
Blaser, M. J., 983
Blattner, W. A., 1235
Blum, M. R., 489
Blundell, N., 1038
Bohnsack, J. F., 823
Boiteux, J.-P., 1400
Bolin, C. A., 246
Bolton, D. C., 1198
Borian, F. E., 570
Borrow, P., 186
Boswell, R. N., 193
Boue, F., 666
Bowden, R. A., 773
Boyle, M. D. P., 965
Bradley, D. W., 355
Brady, L. J., 965
Brady, L. M., 499
Breinig, M. K., 124
Brenneman, G., 719
Brew, B. J., 1079
Brey, R. L., 193
Britt, W., 917
Broggini, M., 1398
Brummett, R. E., 13
Brummitt, C. F., 423
Brunham, R. C., 510, 524, 661
Brüssow, H., 588
Budinsky, A., 660
Buescher, E. S., 1140
Buffone, G. J., 1177
Bugelski, P., 1065
Bugert, J., 898
Buller, M., 893
Burke, D. S., 876
Burke, J. P., 903
Burkhart, K., 719
Burns, B., 1261
Burns, J., 859
Burns, W. H., 596
Busch, M. P., 1088
Butler, T., 742
Byrne, B. C., 1158
Cairo, M. S., 1268
Calandra, T., 312
Campbell, G. H., 868
Campbell, J. R., 325
Campbell, P. A., 1309
Cantin, E. M., 1382
Caprioli, A., 647
Carlisle, J. T., 244
Carpenter, T., 7
Catlin, B. W., 529
Cattaneo, R., 144
Causey, D. M., 1185
Chadee, K., 398
Chai, C. Y., 633
Chakraborty, J., 60, 372
Chambers, H. F., 7
Chan, L. S., 366
Chandler, F. W., 480
Chang, R., 633
Chang, S. A., 633
Chang, Y. H., 633
Chanock, R. M., 1261
Chapelle, N., 1400
Charache, P., 563
Chatfield, S., 1329
Cheeks, J., 518
Chen, C. J., 633
Cherrington, J. M., 423
Chevallier, I., 89

Chidiac, C., 646
Chikami, G., 460
Chiodi, F., 866
Chiu, C. Y., 719
Chou, T.-C., 378
Chow, A. W., 1142
Clabots, C. R., 731
Clark, H F., 570
Classen, D. C., 903
Cleary, P. P., 1317
Clemens, J. D., 60, 372
Clements, M. L., 1209, 1261
Clotet, B., 894
Cluzel, P., 1400
Coca, A., 1139
Cochi, S. L., 1253
Cohen, M. L., 651
Cohn, D. L., 983
Coleman, J. L., 667
Coleman, L. A., 378
Colodny, S. M., 1144
Colombel, J. F., 1395
Concus, A. P., 897
Cook, M. L., 117
Cooper, D. A., 186, 386
Cooper, E. C., 780
Corey, L., 109, 1227
Cortot, A., 1395
Courtright, P., 1347
Coutinho, R. A., 615
Cox, R. A., 1302
Craig, W. A., 200, 831
Crawford, S., 773
Crespo, M. J., 896
Cross, S. M., 186
Crowe, S., 862
Crowell, D. J., 355
Croxson, T. S., 795
Cullison, J. P., 650
Cunningham, A. L., 386, 499
Currie, B., 868
Daffos, F., 138
Dagan, R., 488
Danforth, D., 510
Daniel, R. W., 176
Daniel, T. M., 468, 677
Daphtary, U. D., 965
Darai, G., 898
Datta, P., 524
Davidson, A. J., 983
Davidson, B. L., 483
Davidson, G. P., 477
Davidson, M., 36
Davies, D. R., 789
Davis, C. E., 1398
Davis, J. J., 649
Dawson, C. R., 1347
Dawson, J., 217
De Cock, K., 1170
de Man, P., 29
de Miranda, P., 489
de Salamanca, R. E., 896
de Thé, G., 789
de Wolf, F., 615
Dekonenko, E. J., 748
Delfraissy, J.-F., 666
Dellinger, E. P., 908
DeMaria, A., Jr., 291, 301
Demmler, G. J., 1177
Denhollander, C., 242
Desgranges, C., 789
Deteix, P., 1400
Di Vincenzo, C. A., 1102
Diamond, R. D., 1056
Diaz, P. S., 1245
Dick, E. C., 888
Dickinson, D. P., 205
DiGiacomo, R. F., 1133
Dillon, H. C., Jr., 948
Dimpudus, A. J., 325
Dinarello, C. A., 1017
Divine, G. W., 443
Dobbins, J. J., 203
Dobbs, S., 773
Dobson, S. R. M., 940
Domingo, P., 496
Donelli, G., 647
Donta, S. T., 1147, 1148
Dougan, G., 1329
Douglas, J. M., Jr., 983
Downs, M., 1302
Dreis, M. W., 474
Drew, W. L., 449
Druckman, D. A., 464
Drummond, J. E., 1235
Drutz, D. J., 901
Dryja, D. M., 205
Dubois, D. R., 876
Dubreuil, P., 666
Dummer, J. S., 124
Duncan, J. L., 1379
Dunkle, L. M., 109
DuPont, H. L., 505, 640, 1108
Durant, H., 101
Durno, A. G., 378
Dwyer, D. E., 499
Dylewski, J., 659
Ebert, S. C., 200, 831
Echeverria, P., 640
Eckels, K. H., 876
Edelman, C., 423
Edelman, R., 814
Edwards, M. S., 471, 724
Edwin, C., 1287
Ehrlich, G. D., 1158, 1193
Eiden, J. J., 657, 1120
Eijk, P. P., 360
Eisenberg, M., 934
Ellis, M., 1268
Ellner, J. J., 1302
Elo, J., 996
Elsayed, A., 70
Elwood, R. K., 687
Ena, J., 896
Enarson, D. A., 687
Eng, T. R., 1410
Epstein, L., 1277
Eskola, J., 973
Evermann, J. F., 1133
Facklam, R., 36
Fainstein, V., 655
Faix, R. G., 349
Fan, K. Y., 633
Farci, P., 795
Fass, R. J., 669
Fauci, A. S., 627
Feder, H. M., Jr., 243
Fekety, R., 349
Feldmeier, H., 1368
Fenu, S., 647
Ferne, M., 488
Ferrara, A., 132
Ferrer, J. F., 1133
Fierer, J., 460
Fishbein, D. B., 217, 497
Fisher-Hoch, S. P., 872
Florman, A. L., 1401
Forestier, F., 138
Formal, S. B., 737
Forward, K., 1146
Fournier, L., 1395
Fourrier, A., 646
Fox, R., 464
Foz, M., 894
Frasch, C. E., 343, 710
Freedman, D. O., 556
Frei, R., 654
Frenette, C., 1128
Frey, C. L., 901
Friedman, M. G., 814
Fujita, Y., 1296
Furucrona, A., 866
Gabriel, M., 983
Galant, S., 1268
Galil, A., 814
Gallin, J. I., 627
Gambertoglio, J., 862
Garcia-Monco, J. C., 667
Gazuy, N., 1400
Gelb, A. M., 795
Gelb, L., 132
Gemski, P., 737
Gentile, G., 647
Gerding, D. N., 731
Gerin, J. L., 151
Gershon, A. A., 132
Gibbons, A. E., 23
Gibbons, V. L., 499
Gicquelais, K., 224
Gigliotti, F., 848
Gilbert, B. E., 443
Gilbert, D. N., 13, 909
Gill, M. J., 242

Gillis, Z. A., 1026
Gilsdorf, J. R., 643
Givner, L. B., 724
Glass, R. I., 1112, 1117, 1147
Glauser, M. P., 312
Gocke, D. J., 1135
Gold, D., 1227
Gold, J. W. M., 804
Goldstein, L., 1170
Goldstein, R., 1065
Goldsworthy, W., 477
Gombert, M. E., 238
Gomez-Mateos, J. M., 653
Gonzalez, L. A., 823
Goormastic, M., 884
Gordon, S. M., 489
Gorensek, M. J., 884
Goto, H., 872
Goudsmit, J., 615
Gouvea, V., 570
Grangeot-Keros, L., 138, 666
Graniniger, W., 1368
Gratwohl, A., 654
Gray, B. M., 948
Graybill, J. R., 623
Grayston, J. T., 1095
Greenberg, A. E., 1403
Greenough, W. B., III, 1147
Greer, D. L., 244
Gresser-Burns, M., 487
Griffin, D. E., 433
Griffin, P. M., 668
Groeneveld, K., 360
Grohman, G. S., 386
Gubler, D. J., 876
Gudmundsson, S., 831
Guijon, F., 510
Guiney, D., 460
Gupta, S., 1268
Gust, I., 895
Guthrie, R., 907
Guzman, R., 1146
Gyorkos, T. W., 1128
Haarr, L., 117
Hackbarth, C. J., 7
Hackl, M., 488
Hafez, S. F., 1347
Hakim, S., 1268
Hall-Craggs, M., 1341
Halsey, N. A., 1261
Hammerschlag, M. R., 132, 457
Hammond, M., 650
Hammons, G. T., 702
Hancock, M. L., 1406
Handsfield, H. H., 881
Hankins, G. D. V., 501
Hanna, N., 1065
Hano, J. H., 1102
Harding, G., 494
Harkness, J., 386
Harris, J. R., 60, 372
Hartley, J. W., 900
Haslam, R., 477
Hatlen, L., 460
Hayden, F. G., 166
Healy, D. P., 1413
Heffernan, E. J., 460
Helfand, R. F., 897
Helms, C. M., 702
Herrmann, J. E., 182
Herrmann, M., 693
Herschkorn, S. J., 500
Hessen, M. T., 542
Heyman, M. B., 649
Heyward, W., 1170
Hierholzer, J. C., 804
Hierholzer, W. J., Jr., 212
Hill, C. C., 1098
Hill, H. R., 823
Hill, L. R., 1382
Hiner, E. E., 343
Hipkiss, J. B., 859
Hirabayashi, Y., 872
Hirsch, M. S., 176, 378
Ho, M., 124, 633
Ho, M-S., 1112
Hoagland, M., 1046
Hoffler, E., 1092
Hoffman, S. L., 325
Hoiseth, S. K., 643
Hollander, H., 855, 1088
Holmgren, J., 60, 372, 1147
Holt, D. A., 650
Hood, A. F., 1046
Hook, E. W., III, 881
Hook, J., 1065
Hooton, T. M., 1098
Hopfer, R., 655
Hopkin, J. M., 859
Hopkins, S. G., 1133
Hossain, K. M. B., 1147
Houghton, D. C., 13
Houk, R. W., 193
Houriez, S., 646
Houser, H. B., 742
Houweling, J. T. M., 615
Howard, D. H., 232
Hoy, J. F., 1071
Huber, C., 488
Huda, N., 60, 372
Hudson, R. W., 182
Hughes, W., 848
Hugin, A., 893
Hunter, E., 1245
Hunziker, T., 905
Huq, I., 1147
Hutcheson, R. H., 1253
Hutchins, S. S., 480
Hwang, S. J., 633
Hyslop, N. E., 244
Ikejima, T., 1017
Imada, Y., 1296
Imber, M. J., 897
Inhorn, S. L., 888
Innes, D. J., 166
Innis, B. L., 876
Isaksson, B., 866
Islam, A., 742
Jacobs, M. R., 468
Jacobson, J. A., 1105
Jacobson, M. A., 489, 862
Jaffe, H. W., 1360
Jakubowski, A., 687
Janoff, E. N., 983
Jansen, H. M., 360
Jayashree, S., 1117
Jennings, L. C., 888
Jett-Goheen, M., 1046
Jewesson, P., 1142
Jodal, U., 29
John, J. F, Jr., 1
Johns, M. A., 291, 301
Johnson, J. R., 493, 495
Johnson, M. L., 398
Johnson, P. C., 236
Johnson, R. T., 433
Johnson, W. D., Jr., 910
Joly, J. R., 1412
Jones, W. K., 1154
Jordan, M. C., 423
Josephson, A., 238
Judson, F. N., 983
Juni, B. A., 423
Junkins, J. M., 1046
Kaatz, G. W., 537
Kahan, B. D., 236
Kahlon, J., 925
Kan, V. L., 407
Kantele, A. M., 1011
Kao, J., 766
Kaper, J. B., 70, 224
Kapikian, A. Z., 814, 1261
Kaplan, E. L., 1317
Kaplan, J. C., 378
Kapusnik, J. E., 7
Karp, J. E., 1046
Kascsak, R. J., 1198
Kass, E. H., 44, 677, 1287
Kasworm, E. M., 1105
Katzenstein, D. A., 423
Katzir, G., 814
Kauffman, C. A., 212
Kawasaki, T., 1296
Kay, B. A., 60, 372
Kayes, K., 917
Käyhty, H., 209, 973
Keay, S., 934
Kellogg, D., 1193
Kennedy, D. L., 474
Kessler, E. R., Jr., 669
Kessler, H. A., 1132
Keys, T. F., 884
Khan, M. R., 60, 372, 1147

Khan, M. U., 60, 372
Khoday, S., 659
King, T. E., Jr., 1309
Kirkpatrick, C. E., 909
Kirkpatrick, J., 1146
Kirsh, R., 1065
Kleinfeld, D. I., 1147
Kline, R. L., 483
Klotz, S. A., 636
Klugman, K. P., 956
Knight, V., 443
Koellner, P., 246
Kohlhepp, S. J., 13
Kohnen, P. W., 13
Koornhof, H. J., 956
Kopecky, K. J., 773
Korhonen, T. K., 495, 996
Kosseim, M. L., 510
Kovacs, J. A., 254
Koyama, A. H., 664
Kozeny, G. A., 1102
Kraiselburd, E., 876
Krantz, I., 991
Kravchuk, L. N., 748
Krebs, J., 1170
Kreek, M. J., 795
Kreiswirth, B. N., 549
Kremsner, P. G., 1368
Krook, A., 866
Krowka, J. F., 1088
Kumar, R., 1117
Kurata, T., 872
Kureishi, A., 1142
Kuritsky, J. N., 474
Kurtz, J. B., 182
Kusne, S., 124
Kwok, S., 1158, 1170, 1193
Lafon, S. W., 503
Laga, M., 524
Lai, M. E., 795
Lakeman, F. D., 109
Lal, R. B., 1034
Lally, R. T., 487
Landay, A. L., 1132
Landry, M. L., 1220
Lane, H. C., 627
Lange, J. M. A., 615
Lanser, J. A., 664
LaRussa, P., 132
Lastavica, C. C., 1410
Laughlin, L., 325, 681
Laughon, B. E., 464
Law, C., 386
Leclerc, H., 1395
Lee, S., 1170
Leedom, J. M., 366, 1185
Leggett, J., 200, 831
Lehrman, S. N., 503
Leinonen, M., 209, 1095
Lepow, M., 719
Lerner, E. A., 897
Lerner, L., 588
Lescut, D., 1395
Lesmes Serrano, A., 653
Levine, M. M., 70, 224
Levine, P. A., 166
Levine, P. H., 1235
Levison, M. E., 542
Levy, J., 862
Lew, P. D., 693
Lewis, D. E., 1071
Liaw, Y. F., 633
Liebert, U. G., 144
Liedtke, W., 588
Lifson, A. R., 1360
Lim, F., 1146
Limsomwong, N., 1124
Lincoln, K., 29
Lior, H., 70, 224
Lischner, H. W., 1084
Liu, W. T., 633
Livdahl, C., 1317
Lizizi, Y., 666
Longnecker, R., 602
Loos, B. G., 205
Lopez-Soto, A., 1139
Lorincz, A., 1347
Louv, W. C., 518
Lucas, C. R., 895
Luchetti, M. E., 243
Lum, M., 719
Lyman, C. A., 1056
McCabe, R., 1408
McCabe, W. R., 291, 301
McCloskey, R. V., 1405
McConnell, M. M., 663
McCormick, J. B., 872, 1170
McCrae, M. A., 657
McDade, J. E., 497
McDonald, G. A., 228
McDowell, J., 510
McHenry, M. C., 884
McHugh, T. M., 1088
McIlheran, S. M., 1140
McKee, K. T., Jr., 325
McKevitt, M., 1098
McLaren, L. C., 1401
Maclean, I. W., 661
MacLean, J. D., 1128
McManus, N., 862
McNutt, L.-A., 702
Maassab, H. F., 1209
Machicao, A. R., 468
Maehara, N., 1387
Maitha, G., 524
Mäkelä, O., 973
Mäkelä, P. H., 996
Makino, S., 1387
Makowka, L., 124
Mancebo, J., 496
Mandelli, F., 647
Maneval, D., 70
Mann, R. E., 228
Manning, P. A., 664
Margalith, M., 814
Markowitz, L. E., 480
Marrie, T. J., 101
Marriott, D., 386
Marshall, D. W., 193
Martin, L. N., 1277
Martin, W. J., 1185
Martinez Parra, D., 653
Martino, P., 647
Marwoto, H., 325
Masecar, B. L., 212
Maskell, D., 1329
Massanari, R. M., 702
Masur, H., 254
Mathewson, J. J., 640, 1108
May, R. A., 1177
Meadors, G. F., 876
Megran, D. W., 661
Meignier, B., 602
Meister, B., 488
Melcher, G. P., 193, 901
Melnick, D. A., 1056
Merigan, T. C., 934
Merz, W. G., 1046
Meyers, J. D., 773
Micozzi, A., 647
Midthun, K., 814, 1261
Mietens, C., 588
Milch, L. J., 228
Miller, G. G., 1071
Miller, G. P. G., 236
Miller, K. D., 868
Mills, J., 489, 862
Mills, J. T., 44
Mills, S. E., 166
Miniter, P., 415
Mink, K. A., 888
Mintz, E., 101
Mitchell, C. D., 480
Mitchell, G. H., 789
Mizuochi, T., 893
Mobley, H. L. T., 221
Mocca, L. F., 710
Modesto, K., 570
Modlin, R. L., 366
Moench, T. R., 433
Moesli, P., 905
Moncada, J., 1347
Montelaro, R. C., 1277
Moreau, J. M., 1170
Morgenthaler, J. J., 89
Morrissey, A. B., 468
Morse, H. C., III, 893, 900
Moseley, S. L., 224
Moser, C., 1139
Mosley, B. D., 848
Moss, B., 1382
Moxon, E. R., 859
Muga, R., 894

Muir, P., 494
Mulligan, M., 868
Muncie, H. L., Jr., 1341
Murphey-Corb, M., 1277
Murphy, B. G., 549
Murphy, B. R., 1209
Murphy, E. L., 1235
Murphy, P. M., 627
Murphy, T. F., 761
Murray, B. E., 640
Murray, H. W., 1372
Musey, K. L., 646
Nagal, M., 1296
Nahmias, A. J., 109
Nakamura, Y., 1296
Nakayama, T., 1387
Nash, D. R., 52
Nataro, J. P., 70, 224
Nath, S. K., 742
Nathan, C. F., 1372
Ndinya-Achola, J. O., 524
Negro, F., 151
Neill, R. J., 737
Neimes, R. E., 1302
Nelson, R., 907
Neogy, P. K., 372
Net, A., 496
Newland, J. W., 737
Nguyen-Dinh, P., 1403
Nicolle, L. E., 494
Niederwieser, D., 488
Nielsen, J. L., 501
Nolla, J., 496
Norden, C. W., 660
Norman, D. C., 355
Norris, S. A., 1324
Norris, S. J., 236
Norton, D. R., 13
Notkins, A. L., 1382
Novick, D. M., 795
Novick, R. P., 549
Numsuwan, V., 1135
Nutman, T. B., 868
O'Callaghan, D., 1329
O'Leary, T., 80
Obriecht, C. R., 433
Odehouri, K., 1170
Ognibene, A. J., 1302
Ogra, P. L., 160
Oka, S., 872
Okusawa, S., 1017
Openshaw, H., 1382
Orozco, E., 398
Osano, M., 1387
Ottesen, E. A., 556, 1034
Ou, C.-Y., 1154, 1170
Overturf, G. D., 366
Paleologo, F. P., 325
Panelius, J., 1095
Pang, L., 1124
Paradis, T. J., 378
Pardridge, W. M., 630
Parish, S. M., 1133
Parkinson, A., 36
Parr, T. R., Jr., 1003
Parris, D., 1065
Parsonnet, J., 44, 1026, 1287
Patterson, J. E., 212, 1144
Patterson, L. E. R., 471
Patterson, T. F., 415
Paul, D. A., 1132
Peeling, R., 661
Peigue-Lafeuille, H., 1400
Pere, A., 495
Perron-Henry, D. M., 182
Pesanti, E. L., 1137, 1353
Peters, G., 693
Peterson, L. R., 731
Petri, W. A., Jr., 398
Pfaller, M. A., 702
Pickard, D., 1329
Pillot, J., 138, 666
Pinsky, P. F., 1112
Piot, P., 524
Pitsakis, P. G., 542
Pittet, D., 693
Pizzo, P. A., 80
Platt, R., 474
Plikaytis, B. D., 651
Plotkin, S. A., 570
Plummer, F. A., 524
Poiesz, B. J., 1158, 1193
Polk, B. F., 464
Polk, R. E., 1413
Pollack, H., 36
Pomeroy, C., 1391
Poolman, J. T., 209
Popper, H., 151
Porter, D. D., 117
Porter, G. A., 13
Poste, G., 1065
Postlethwaite, R., 898
Potempska, A., 1198
Pottage, J. C., Jr., 1132
Powell, D. A., 109
Prado, V., 70, 224
Preblud, S. R., 480
Price, R. W., 1079
Procell, P. M., 868
Punjabi, N. H., 325
Purcell, R. H., 151
Putkonen, P., 866
Quadrelli, C., 1398
Quan, J., 651
Quandalle, P., 1395
Quinn, T. C., 464, 483
Quinnan, G. V., Jr., 780
Raff, M. J., 203
Raj, P., 1117
Raja, A., 468
Rampling, A., 1336
Rand, F., 510
Rao, M. R., 60, 372
Ravaud, Y., 492
Ravdin, J. I., 398
Rayfield, M., 1170
Rayner, E., 510
Redd, S. C., 651
Reesor, C., 1142
Rehg, J. E., 1406
Reiser, R. F., 1105
Reisner, H., 898
Rench, M. A., 471
Rhame, F. S., 423
Ribera, A., 894
Rich, R., 36
Rinaldi, M. G., 901
Ringenbergs, M., 477
Ristic, M., 217
Rizkallah, M. F., 1092
Roach, K. C., 480
Roberson, R., 991
Roberts, J. M., 868
Roberts, M. A., 217
Robins-Browne, R., 70, 224
Rocha, R. M., 1368
Roddy, R. E., 881
Roizman, B., 602
Roldan, E. O., 480
Ronald, A. R., 524
Roos, R. P., 144
Rösen-Wolff, A., 898
Rossi, S., 1398
Rotstein, O. D., 766
Rowe, B., 663
Rowland, J., 483
Royo Balbontin, A., 653
Rubin, R. H., 176
Rustama, D., 325
Rutherford, G. W., 1360
Ruutu P., 1095
Ryan, J. L., 415
Saarinen, L., 973
Sack, D. A., 60, 372
Sahai, J. V. S., 1413
Said, M. E., 1347
Saikku, P., 1095
Saldana, M. J., 480
Samorodin, R., 1261
Sampietro, C., 1398
San Joaquin, V., 109
Sanchez Porto, A., 653
Sande, M. A., 7
Sandford, G. R., 596
Sanjaya, B., 325
Saral, R., 563
Sarov, B., 814
Sarov, I., 814
Sasaki, K., 1387
Satterfield, W. C., 151
Saukkonen, K., 209
Savage, C., 1395
Savici, D., 1309

Savoia, M. C., 1396
Sawyer, L. A., 497
Schaad, U. B., 89, 905
Schaberg, D. R., 212, 349
Schachter, J., 1347
Schaffner, W., 1253
Scheidegger, C., 654
Schellekens, J., 312
Schellekens, P. T., 615
Schimbor, C. M., 1177
Schlievert, P. M., 44, 549
Schmidli, J., 905
Schnebli, H. P., 89
Schneebaum, C. W., 795
Schochetman, G., 1154, 1170
Scholz, J., 898
Schooley, R. T., 378
Schoolnik, G. K., 332
Schumacher-Perdreau, F., 693
Schuster, D. M., 651
Schwartz, L. B., 1413
Schwartzer, T. A., 1135
Sciortino, C. V., 1324
Scott, G. B., 480
Scott, L. D., 236
Sculley, T. B., 186
Sears, S. D., 1209, 1261
Seligson, D., 203
Sell, S., 236
Sellers, P. W., 934
Senie, R. T., 795
Seo, S. M., 537
Seppälä, I., 973
Shahm J., 366
Shah, K. V., 176, 563
Shanley, J. D., 1353, 1391
Sharpe, R. J., 897
Shearer, G. M., 893, 1391
Sheppard, J., 1347
Shibata, D., 1185
Shigematsu, I., 1296
Shimada, K., 872
Shinners, E. N., 529
Sidoti, J., 588
Sigurs, N., 991
Siitonen, A., 996
Silcox, V. A., 52
Simons, E. R., 1056
Singer, A., 893
Singh, N., 124
Singharaj, P., 1124
Sinnott, J. T., IV, 650
Skjold, S., 1317
Smith, A. L., 742
Smith, C. B., 903
Smith, J. W., 1137
Smith, S., 1245
Sninsky, J. J., 1158, 1170, 1193
Snyder, M. H., 1209
Soave, R., 910
Solberg, G., 1227
Soong, S. -J., 109
Soriano, V., 894
Sotek, J., 588
Spear, J. B., 1132
Speirs, G., 1336
Sperber, S. J., 166
Spielman, A., 1410
Spika, J. S., 651
Stagno, S., 518
Stamm, W. E., 1098
Stanton, B. F., 60, 372
Starzl, T. E., 124
Steele, J. H., 915
Steele, R. W., 109
Steere, A. C., 748, 754
Steinberg, S. P., 132
Steinhoff, M., 1261
Stephens, D. S., 332
Stevens, D. L., 23
Stevens, J. G., 117
Stewart, R. W., 884
Stewart, T. J., 859
Stites, D. P., 1088
Stiver, H. G., 661
Stoeckel, K., 742
Story, B., 934
Stricker, R. B., 1088
Sumaya, C. V., 109, 193
Sun, M., 160
Surampaet, B., 325
Suter, S., 89
Svanborg Edén, C., 29
Svennerholm, A.-M., 60, 372
Sweeney, M. S., 650
Sypek, J. P., 392
Taber, L. H., 940
Tachedjian, G., 895
Takanen, R., 1011
Tall, B., 224
Taniguchi, K., 814
Tao, H., 657
Taranger, J., 991
Tarloff, J., 1065
Tauxe, R. V., 668
Taylor, J. P., 217
Taylor, M. B., 795
Teng, N., 934
ter Meulen, V., 144
Terasaki, T., 630
Thaler, M., 80
Thomas, F., 492
Tierney, A. J., 1375
Tilg, H., 488
Tindall, B., 386
Tor, J., 894
Torre, D., 1398
Tosi, M. F., 457
Toy, C., 1268
Trifillis, A. L., 221
Trollfors, B., 991
Tsai, C.-M., 710
Tsukamura, M., 52
Tuomanen, E., 36
Tupasi, T. E., 1095
Turnidge, J., 831
Uchida, T., 664
Uchiyama, T., 664
Umphrey, J., 655
Urano, T., 1387
Urasawa, S., 814
Vachon, L. A., 366
Vadhan-Raj, S., 1140
Vaisberg, A. J., 433
Valls, V., 896
van Alphen, L., 360
Van Buren, C. T., 236
van der Meer, J. W. M., 1017
van der Noordaa, J., 615
Van Drunen, N., 423
VandeVen, C., 1268
Vankemmel, M., 1395
Vaudaux, P. E., 693
Vaudry, W. L., 1375
Venditti, M., 647
Venezio, F. R., 1102
Verhoef, J., 312
Vernon, A. A., 464
Via, C. S., 1391
Vial, P. A., 70, 224
Vincent, P., 1395
Vogelman, B., 200, 831
Vogt, M. W., 378
Volberding, P., 489
Vonderfecht, S. L., 657, 1120
Vujcic, L. K., 780
Waag, D. M., 101
Wagner, E. K., 117
Wakefield, A. E., 859
Wakefield, D. S., 702
Waldvogel, F. A., 693
Wallace, R. J., Jr., 52
Wang, L. Y., 710
Wang, S. R., 633
Wanger, A. R., 640
Ward, J. I., 719
Warren, J. W., 221, 1341
Warren, R. E., 1336
Wartgow, C. D., 888
Waters, D. J., 1235
Watson, E. A., 1277
Watt, G., 681
Wedderburn, N., 789
Weeks, K. E., 754
Weiss, S. H., 1235
Wenman, W. M., 1375
Werchau, H., 588
West, M., 1277
Westerlund, B., 996
Westin, E. H., 1413
Wharton, M., 1253
White, M. I., 898
Whitley, R. J., 109, 925

Whitney, A. M., 332
Wiedermann, G., 1368
Wigand, R., 804
Wiley, J., A., 500
Willey, D. E., 1382
Williams, J. C., 101
Williams, P. H., 996
Wilson, M., 1261
Wilson, M. L., 1410
Winn, R. E., 193
Winn, V., 23
Winn, W. C., 1412
Winsor, D. K., Jr., 1108
Wise, M. G., 193
Wong, E. S., 1098
Wong, S. F., 366
Wood, C. A., 13
Woodmansee, D. B., 1406
Woolfrey, B. F., 487
Woolson, R. F., 702
Woskobnick, R., 907
Wright, P. F., 109
Wu-Hsieh, B., 232
Wyler, D. J., 320, 392
Yamashita, T. S., 1302
Yanagawa, H., 1296
Yang, K. D., 823
Yashiro, M., 1296
Yih, J., 355
Yolken, R. H., 657, 1120
Yow, M. D., 1153
Yu, C. P., 443
Yunus, M., 60, 372
Zackrisson, G., 991
Zahradnik, J. M., 710
Zak, O., 36
Zaki, S., 1347
Zanen, H. C., 360
Zaraspe, G., 681
Zervos, M. J., 212, 1144
Zhang, J.-y., 1277
Zhaori, G., 160
Zibello, T. A., 1220
Ziegler, E. J., 286
Zollinger, W. D., 332
Zotter, G. M., 1368

Subject Index

AIDS
  adenosine deaminase activity as test for meningeal tuberculosis, 896
  AIDS-like disease, due to SIV, in rhesus monkeys, 1277
  and defective lymphocyte chemotaxis, 1398
  and diarrhea, role of gastrointestinal viruses, 386
  and HIV infection, position paper, 273
  antibodies to EBV, 186
  C. neoformans infection mimicking molluscum contagiosum, 897
  $CD4^+$ cell numbers and HIV core antigens and antibodies as predictors, 615
  $CD8^+$ T helper cell function, 893
  CMV infection, 449
    treatment with ganciclovir and zidovudine, 489
  course of illness, two months after primary HIV infection, 866
  dementia complex, 1079
  fatal measles pneumonia in a child, 480
  food counseling for patients with, 668
  Foscarnet therapy for HIV infection, 862
  histoplasmosis in, 623
  HIV antigen, antibody, and immune complexes, 1088
  humoral responses to *S. pneumoniae* vaccines, 983
  impaired neutrophil bactericidal capacity, 627
  impaired polymorphonuclear leukocyte function in, 1268
  infection with different adenovirus types, 804
  recovery of *Campylobacter* from homosexual or bisexual men, 464
  serological markers of HIV infection, in African and European/American patients with AIDS, 894
  sulfated polysaccharides as antiviral agents against HIV-1, 1084
  surface markers of monocyte function and activation, 483
AIDS Commentary
  AIDS dementia complex, 1079
  CMV infection, 449
  CSF findings, 855
  histoplasmosis, 623
  natural history of HIV infection, 1360
  P. carinii pneumonia, therapy and prophylaxis
AIDS-related complex
  and *L. monocytogenes* meningitis, 1396
  impaired polymorphonuclear leukocyte function in, 1268
Abcesses, intra-abdominal, *See* Intra-abdominal abscesses
Actinomycetoma, of hand, due to *N. asteroides*, 244
Acyclovir
  chronic-dose, in recurrent HSV infection, 1227
  effect on HSV antibody, 1227
Adenosine deaminase activity, in CSF, test for meningeal tuberculosis in AIDS, 896
Adenovirus
  human, new serotypes and intermediate strains, 804
  serotypes, in patients with AIDS, 804
Adenovirus 3a, molecular epidemiology of nosocomial outbreak, 423
Adherence
  due to enteroadherent-aggregative *E. coli*, 70
  of *E. coli*, effect of Tamm-Horsfall protein, 1379
  S. aureus and coagulase-negative staphylococci, 693
Amikacin, pharmacokinetics and pharmacodynamics in experimental pseudomonas endocarditis, 355
Aminoglycosides
  dosing regimens, perspective, 1
  resistance factor, in *P. aeruginosa*, 1324
  resistance to and uptake, in experimental *P. aeruginosa* endocarditis, 1003
Amoxicillin-clavulanate, use in a patient with Lyme facial palsy, 905
Amphotericin B
  emulsion, for treating systemic candidiasis in mice, 1065
  for treating
    experimental aspergillosis, 415
    fusariosis, 1046
Ansamycin, combined with zidovudine, for in vitro HIV infection, 895
Antibody, to Re mutant of *S. minnesota*, protective immunoglobulin class, 291
Antifungal agents, in a rabbit model of candidiasis, 80
Antimicrobial agents
  correlation of pharmacokinetic parameters with efficacy, 831
  guidelines for use, 908, 909
Antimicrobial resistance, of serogroups of *S. pneumoniae* causing bacteremia and meningitis, 956
Aspergillosis, invasive, experimental infection and amphotericin B treatment, 415
Aspergillus fumigatus
  binding by lectin-like attachment sites on murine pulmonary alveolar macrophages, 407
  experimental infection, treatment with amphotericin B, 415
Astrovirus, monoclonal antibodies, antigenic characterization of, and cultivation of serotypes 1, 2, 4, and 5, 182
Azidothymidine, *See* Zidovudine
AZT, *See* Zidovudine
Aztreonam, for treating osteomyelitis due to *P. aeruginosa*, 660

Bacteremia
  and meningitis, due to *S. pneumoniae*, antimocrobial resistance of serogroups, 956
  due to *B. catarrhalis*, 907
Bacterial translocation, in colorectal cancer, 1395
Bacteriuria, asymptomatic, in elderly women, 493
Beta-lactam antibiotics, and clinical bleeding during treatment, 669
BK virus
  and JC virus infections of renal transplant recipients, serological investigation, 176
  infections, in marrow transplant recipients, 563
Bleeding
  and treatment with β-lactams, 669
  N-methylthiotetrazole cephalosporins, 1405
Blood-brain barrier, restricted transport of zidovudine and dideoxynucleosides, 630
Bone marrow transplantation
  hospital-acquired cryptosporidiosis, 647
  infections due to BK and JC viruses, 563
  lung cytotoxicity in CMV pneumonia, 773
Borrelia burgdorferi
  antibodies to myelin basic protein in Lyme disease, 667
  cultivated from joint fluid, 905

infection
in the Soviet Union, 748
risk in dogs vs. humans, 1410
serodiagnosis of early infection, 754
Borreliosis, in the Soviet Union, 748
Bovine leukemia virus, trauma and rectal transmission in cattle, 1133
Branhamella catarrhalis
bacteremia due to sepsis, 907
comparison of outer membrane proteins of 50 strains, 761
epidemiology and transmission, 205
strain typing by DNA restriction fragment mapping, 205
Breast milk, human, rotavirus antibodies in, as well as in colostrum and maternal and cord blood, 477
Bronchoalveolar lavage cells, cytotoxic activity against CMV, in marrow transplantation, 773

Campylobacter spp., recovery from homosexual men, 464
Candida spp.
antifungal therapy in a rabbit model, 80
causing disseminated candidasis and gangrenous cholecystitis, 653
Candida albicans
bioemulsifier produced by, 636
infection, in a neonatal unit, 1375
neutrophil signaling due to, role of guanosine triphosphate binding proteins, 1056
Candida krusei, nosocomial outbreak transmitted by lemon juice, 654
Candidiasis
disseminated, and gangrenous cholecystitis, 653
in a neonatal unit, 1375
single-drug vs. combination antifungal therapy in rabbits, 80
systemic in mice, treatment with amphotericin B emulsion, 1065
Cardiac transplantation
CMV infection as risk factor for major infections, 884
L. pneumophila infection, 651
RSV infection, 650
Catheters, long-term urethal, association with pyelonephritis, 1341
Cefaclor, adverse reactions, 474
Cefotaxime, bleeding associated with treatment, 669
Ceftazidime, pharmacokinetics and pharmacodynamics in experimental pseudomonas endocarditis, 355
Ceftriaxone
for incubating and early syphilis, 881
for treating typhoid fever, 742
for Lyme borreliosis refractory to amoxicillin-clavulanate and doxycycline, 905
Cephalosporins, reports of bleeding and hypoprothrombinemia, 1405
Cerebral malaria, *See* Malaria, cerebral
Cerebrospinal fluid
abnormalities, in HIV infection, 193
findings in patients with AIDS, 855
shunts, infection, treatment with vancomycin, 1142
Chagas' disease, treatment with ketoconazole or itraconazole, 1408
Chlamydia, TWAR, associated with acute lower-respiratory-tract infection, in Filipino children, 1095
Chlamydia trachomatis
and infertility, 510
cervical infection, prophylaxis with nonoxynol-9, 518
complement-enhanced neutralizing antibody, 661
infection
in salpingitis, 510
of infants in Nairobi, Kenya, 524
neutralization, effects of complement and MOMP and non-MOMP antibodies, 661
nonculture methods of diagnosing infection in patients with trachoma, 1347
perinatal transmission, 524
stimulation of neutrophils by, 457
Chloramphenicol, for treating typhoid fever, 742
Cholecystitis, gangrenous, caused by *Candida* spp., 653
Cholera
B subunit–whole cell vaccine, cross-protection against enterotoxigenic *E. coli*, 372
oral vaccines, field trial in Bangladesh, 60
Cholera toxin, receptor blockade may prevent disease, 1147, 1148
Ciguatera fish poisoning, common-source outbreak, 1128
Ciprofloxacin, mechanism(s) of resistance to *P. aeruginosa*, 537
Clindamycin
for treating experimental streptococcus myositis, 23
plus quinine, for treating *P. falciparum* malaria, 1368
susceptibility testing, nosocomial outbreak of *C. difficile*, 731
Clostridium difficile
bacteriophage and bacteriocin typing, 349
epidemiology of colonization in newborns, 349
plasmid profile typing of nosocomial strains, 731
Clostridium tertium, septicemia, in patients with neutropenia, 1336
Coccidioides immitis, meningitis due to, treatment with fluconazole, 903
Colonization factor antigens, fibral types, 663, 664
Colony-stimulating factor, recombinant granulocyte-macrophage, effects on neutrophil function, 1140
Colorectal cancer, bacterial translocation, 1395
Common cold, lack of fomite transmission, 888
Complement, enhanced neutralization of *C. trachomatis*, 661
Condyloma acuminata, treatment with topical interferon, 934
Corticosteroids
and heparin, for treating retinal arterial occlusion in Mediterranean spotted fever, 1139
use of dexamethasone to treat cerebral malaria, 325
Coxiella burnetii, exposure to parturient cats as a risk factor for Q fever, 101
Cryptococcosis, cutaneous, mimicking molluscum contagiosum, in AIDS, 897
Cryptococcus neoformans
cross-reaction of capsular polysaccharide with *T. beigelii* cell wall, 901
in vitro T cell responses in HIV infection, 1071
infection, mimicking molluscum contagiosum, in AIDS, 897
Cryptosporidiosis
atypical oocysts, 1038
chronic, in an immunodeficient adolescent, 649
hospital acquired, in marrow transplant recipients, 647
treatment with dexamethasone, in rats, 1406
Cryptosporidium
causing sinusitis in an immunodeficient adolescent, 649
extraintestinal involvement, 649
Cryptosporidium spp., animal reservoirs, transmission, 909, 910
Cystic fibrosis, fibronectin-cleaving activity in bronchial secretions, 89

Cytomegalovirus
cytotoxicity to, in lungs after marrow transplantation, 773
infection
after liver transplantation, effect of OKT3 antibodies, 124
as risk factors for major infections, after cardiac transplantation, 884
in AIDS, 449
in marrow recipients, treatment with ganciclovir and hyperimmunoglobulin, 488
murine, interstitial pneumonitis, 1391
primary, in pregnant women, 917
mouse, temperature-sensitive mutants as vaccines, 596
polymerase chain reaction for detecting DNA
in blood, 1185
in urine, 1177
transmission in utero, antibodies to viral proteins, 917
Cytotoxicity
against CMV in the lung after marrow transplantation, 773
HLA-restricted, in VZV, 780

Dementia complex, in AIDS, 1079
Dengue virus
attenuation, for use as vaccine in humans, 876
type 3, vaccine trial, 876
Dexamethasone
for treating cerebral malaria, 325
rat model of cryptosporidiosis, 1406
Dextran sulfate, antiviral agent against HIV, 1084
Diarrhea
acute, IgA-secreting cells, 1011
due to
E. coli, detected by DNA probes, 224
enteroadherent-aggregative *E. coli*, 70
rotavirus, 1112
protective effect of WC3 vaccine, 570
potential for prevention, by blockade of cholera toxin receptors, 1147, 1148
Diarrhea, travelers', *See* Travelers' diarrhea
Dideoxycytidine, synergism with recombinant IFN-α-A against HIV-1, 378
Dideoxynucleosides, restricted transport through the blood-brain barrier, in rats, 630
DNA
cloning from *P. carinii*, 859
restriction profiles, *S. pyogenes*, 1317
Dosing regimens, correlation of pharmacokinetic parameters with efficacy, 831
Doxycycline
low-dose, prophylaxis for malaria, 1124
use in a patient with Lyme facial palsy, 905

Eagle effect, efficacy of clindamycin, erythromycin, and penicillin in streptococcal myositis, 23
Echovirus 27, isolation from amniotic fluid, and intrauterine fetal death, 501
Ehrlichia canis, human infection in Texas, 217
Encephalitis
measles, absence of detectable virus in the CNS, 433
measles inclusion body, restriction of measles virus gene expression, 144
Endocarditis, experimental
due to *P. aeruginosa*
aminoglycoside resistance, 1003
pharmacokinetics and pharmacodynamics of amikacin and ceftazidine, 355
treatment with imipenem, 542
postantibiotic effect, 542
Endotoxin, protective antibody to, perspective, 286
Entamoeba histolytica, Gal/GalNAc adherence lectin, 398
Enterococci, heterogeneity of gentamicin resistance plasmids, 212
Epidemiology
antibodies to *S. pneumoniae* polysaccharides in infants, 948
C. difficile colonization in newborns, 349
molecular, of an adenovirus 3a outbreak, 423
of HDV and HIV, in parenteral drug abusers, 795
Epiglottitis, due to *H. influenzae* type b, in vaccinated children, 343
Epitope, toxic-shock-syndrome toxin-1, *S. aureus*, 549
Epstein-Barr virus
and *P. brasilianum*, development of glomerulonephritis in marmosets, 789
antibodies, and HIV infection, 186
infection after liver transplantation, effect of OKT3 antibodies, 124
Erythema infectiosum, during pregnancy, 659
Erythromycin, for treating experimental streptococcal myositis, 23
Escherichia coli
adherence, effect of Tamm-Horsfall protein, 1379
and receptor blockade, 1147, 1148
attachment and inflammation in the urinary tract, 29
detection of diarrheagenic strains by DNA probes, 224
enteroadherent-aggregative, diarrheal disease due to, 70
enteroinvasive, causing travelers' diarrhea, 640
enterotoxigenic, protection conferred by B subunit–whole cell cholera vaccine, 372
from boys with urinary tract infections, 996
Gal-gal specificity and inflammation in the urinary tract, 29
internalization into renal tubular epithelial cells, 221
P fimbriae
and bacteriuria, 494
expression, in urine, 495
virulence factors, fimbriae, and hemolysin, in urinary tract infections, 996
Escherichia coli J5, IgG to, for treating gram-negative septic shock, 312
Escherichia coli O111:B4, vaccine, antibody response in human volunteers, 1135

Fibrinogen, surface-bound, adherence of staphylococci to, 693
Fibronectin
age-associated maturation, susceptibility to group B *Streptococcus*, 471
cleavage
by neutrophil elastase and cathepsin G, 89
in cystic fibrosis bronchial secretions, 89
effect on interaction of PMNLs and bacteria, 823
surface-bound, adherence of staphylococci to, 693
Fifth disease, *See* Erythema infectiosum
Filariasis, human, diagnostic specificity using IgG4 assessment, 1034

Fimbriae, *E. coli*, expression of in urine, 495
5-Fluorocytosine, for treating fusariosis, 1046
Fluconazole, for treating coccidioidal meningitis, 903
Food poisoning, outbreak of ciguatera fish poisoning, 1128
Foscarnet, antiretroviral effect in patients with AIDS, 862
Fusariosis, diagnosis and treatment, 1046
Fusarium solani, diagnosis and treatment of infection, 1046

Gammaglobulin, human, hyperimmune for group B streptococci, protection against GBS disease in neonatal mice and rats, 724
Ganciclovir
  and hyperimmunoglobulin, for treating CMV pneumonitis, 488
  combined treatment with zidovudine, causing prolonged pancytopenia, 489
  for treating murine CMV pneumonitis, 1391
Gastroenteritis, due to rotavirus
  sequential outbreaks, 814
  seroconversion patterns, 588
Gastrointestinal disease, due to *M. tuberculosis*, 687
Gastrointestinal tract, viral infections in HIV-positive, symptomatic homosexual men, 386
Gastrointestinal viruses, role in diarrhea in HIV-infected homosexual men, 386
Gentamicin
  heterogeneous resistance plasmids in enterococci, 212
  with imipenem, absence of postantibiotic effect in experimental endocarditis, 542
Glomerulonephritis, in marmosets infected with *P. brasilianum* and EBV, 789
Graft-vs.-host reaction, and interstitial pneumonitis, in murine CMV infection, 1391
Gram-negative septic shock
  immunotherapy for, 312
  treatment using IgG to *E. coli J5*, 312
Group A streptococci, tolerance to penicillin, 487
Group B rotaviruses, *See* Rotaviruses, group B
Group B streptococci
  fibronectin and age-limited susceptibility, 471
  human hyperimmune IgG preparation increases in vitro opsonophagocytic activity of type III GBS, 724
  novel antigens identified by RIA, 965
Group C streptococci, pneumonia due to, antibody response, 1092

Haemophilus influenzae
  nasopharyngeal colonization during antibiotic therapy, 643
  nontypable, changes in outer membrane proteins, 360
  relationship between type b and nontypable, 643
Haemophilus influenzae type b
  conjugate vaccines, isotype distribution of antibodies, 973
  PRP-pertussis and PRP-D vaccines, response to, 719
  spectrum of disease in vaccinated children, 343
  vaccination, 343
Hepatitis
  due to *C. burnetii*, 497
  syphilitic, after renal transplantion, 236
Hepatitis B virus
  carrier chimpanzees superinfected with HDV, 151
  reappearance and possible reactivation in HIV-1–positive patients, 666
Hepatitis D virus
  and HIV, in parenteral drug abusers, 795
  chronic infection in HBV carrier chimpanzees, 151
Hepatitis viruses, seroepidemiology in prostitutes in Taiwan, 633
Herpes simplex virus
  autoinoculation, 242
  disease and latency, after genital superinfection, 1220
  DNA restriction enzyme analysis of digital and genital isolates, 242
  genetically engineered vaccine, evaluation in rodents, 602
  immunologic factors predictive of outcome in newborns, 925
  infection
    after liver transplantation, effect of OKT3 antibodies, 124
    antibody response of newborns, 925
    changing presentation in neonates, 109
    recurrent genital, treatment with acyclovir, 1227
  latency-associated transcript in trigeminal ganglia, 117
Herpes simplex virus type, 1, acute and latent infection, protection by recombinant vaccinia viruses, 1382
Herpes zoster, localized, source of airborne transmission, 238
Histoplasmosis, and AIDS, 623
HLA phenotype, in tuberculosis, 1302
Human immunodeficiency virus
  and EBV infection, 186
  and HDV, in parenteral drug abusers, 795
  antigen, free and complexed, in AIDS, 1088
  detection of DNA by polymerase chain reaction, 1170
  exposure to, prophylaxis with Retrovir® (zidovudine), 503
  in vitro infection, effect of zidovudine and ansamycin, 895
  infection
    and CSF abnormalities, 193
    assays of antigen-specific T cell function, prediction of progression, 1071
    $CD8^+$ T helper cell function, 893
    course of AIDS two months after primary infection, 866
    detection of CMV DNA in, 1185
    functional vs. phenotypic analysis of T cells, 1071
    impaired polymorphonuclear leukocyte function, 1268
    in AIDS, position paper, 273
    natural history of, 1360
    response to *C. neoformans*, 1071
    risk of, related to number of sex partners, 500
    serological markers, in African and European/American patients with AIDS, 894
    total immunoglobulins, antibody responses to pneumococcal polysaccharide vaccine, 983
    treatment with
      Foscarnet, 862
      sulfated polysaccharides, in AIDS, 1084
  predictive markers of AIDS, 615
  rapid rebound of antigen after discontinuing zidovudine therapy, 1132
Human immunodeficiency virus type 1
  antiviral synergism of dideoxycytidine and recominant IFN-α-A, 378
  infection, relation to outcome of hepatitis B, 666
  mixed infection with HIV-2, 1170
Human immunodeficiency virus type 2, mixed infection with HIV-1, 1170
Human T cell leukemia virus, characterization of a sequence in chronic progressive myelopathy, 1193

Human T lymphotropic virus type 1, patterns of antibody to, by age and risk group, 1235
Human T lymphotropic viruses, seroepidemiology in prostitutes in Taiwan, 633
Hydrogen peroxide, for treating experimental visceral leishmaniasis, 1372
Hypoprothrombinemia, *N*-methylthiotetrazole cephalosporins, 1405
Hypotension, induced by vancomycin, 1413

IgA, response in acute diarrhea, 1011
IgG
  human, to *E. coli* J5, for treating gram-negative septic shock, 312
  response to *B. burgdorferi* in early Lyme disease, 754
  to Re mutant, protective activity after immunization with *S. minnesota* rough mutants, 291
IgG4, assessment as diagnostic method, in filariasis, 1034
IgM
  response to *B. burgdorferi* in early Lyme disease, 754
  to Re mutant, protective activity after immunization with *S. minnesota* rough mutants, 291
Imipenem, absence of postantibiotic effect in experimental endocarditis, 542
Immune complexes, characterization, in congenital syphilis, 940
Immunization, with *S. minnesota* Re mutants, antibody response and reactions and serum protective activity, 301
Immunoglobulins, hyperimmune for CMV, and ganciclovir, for treating CMV pneumonia, 488
Immunosuppression, virus-induced, murine model of susceptibility to infection, 232
Infectious Diseases Society of America
  AIDS and HIV infection, position paper, 273
  final meeting program, 671
  preliminary meeting program, 260
Infertility, associated with *C. trachomatis* infection, 510
Influenza, live and inactivated influenza A vaccines, 1209
Interferon, topical, for treating condyloma acuminata, 934
Interferon-α, production after inoculation with measles vaccine, 1387
Interferon-α-A, recombinant, synergism with dideoxycytidine against HIV-1, 378
Interferon β_{ser}
  prophylaxis for the common cold, 166
  tolerance and efficacy of intranasal administration, 166
Interferon-γ, production after inoculation with measles vaccine, 1387
Interleukin-2 receptor, increased levels in *P. falciparum* malaria, 1403
Interstitial pneumonitis, in murine CMV infection, and graft-vs.-host reaction, 1391
Intra-abdominal abscesses, prevention by fibrinolysis, in rats, 766
Isospora belli
  animal reservoirs, transmission, 909, 910
  in chronic diarrhea, 646
  infection, roxithromycin treatment, 646
Itraconazole, for treating Chagas' disease, 1408

JC virus
  and BK virus infections of renal transplant recipients, serological investigation, 176
  infections, in marrow transplant recipients, 563

Kawasaki disease, incidence survey in Japan, 1296
Ketoconazole, for treating Chagas' disease, 1408

Laminin, surface-bound, adherance of staphylococci to, 693
Lassa fever, imported case, with polyserositis, 872
Lectins
  E. histolytica, 398
  lectin-like attachment sites on murine pulmonary alveolar macrophages bind *A. fumigatus*, 407
Legionella pneumophila
  infections in cardiac transplant recipients, 651
  monoclonal antibody typing, 1412
  subgroups and virulence, 1412
Legionella pneumophila group 4, cross-reacting antibodies in Q fever, 499
Legionellosis, in cardiac transplant recipients, nationwide survey, 651
Leishmania, susceptibility of, to contact-mediated macrophage activation, 392
Leishmania donovani, infection, treatment with H_2O_2, 1372
Leishmaniasis, visceral, experimental, treatment with H_2O_2, 1372
Leptospira interrogans, transmission by milk, 247
Leukocyte function, in patients undergoing hemodialysis, effects of 1,25 dihydroxyvitamin D_3, 1102
Lipopolysaccharide, rough, of *N. meningitidis*, monoclonal antibodies to, 209
Listeria monocytogenes
  alveolar macrophages, bactericidal activity, 1309
  meningitis
    in a patient with ARC, 1396
    rhabdomyolysis and acute renal failure, 492
Liver disease, increased severity with HDV and HIV infections, 795
Liver transplantation, herpesvirus infections, effect of OKT3 antibodies, 124
Lyme disease
  analysis of early IgM and IgG antibody responses, 754
  antibodies to myelin basic protein, 667
  dogs as sentinel animals for surveillance, 1410
  in the Soviet Union, 748
  risk in dogs vs. humans, 1410
Lymphocytes
  chemotaxis, defective, in AIDS, 1398
  $CD4^+$ cell numbers and HIV core antigens and antibodies as predictors, 615

Macrophages
  alveolar phagocytosis and killing of *L. monocytogenes*, 1309
  contact-mediated activation against lymphokine-resistant *Leishmania*, 392
  pulmonary, lectin-like attachment sites on, bind *A. fumigatus*, 407
Magnesium, effect on toxic-shock-syndrome toxin-1, 44
Malaria
  antibodies to *P. falciparum*, in Peace Corps volunteers, early development, 868
  cerebral
    treatment, perspective, 320
    treatment with high-dose dexamethasone, 325
  falciparum
    and increased levels of interleukin-2 receptor, 1403
    antibodies to sporozoites, 868

resistant strains, 1368
treatment with quinine plus clindamycin, 1368
prophylaxis with low-dose doxycycline, 1124
quartan, and EBV in marmosets, development of glomerulonephritis, 789
Measles
fatal
distribution of antigen and RNA, 433
in a child with AIDS, 480
neurological involvement, 433
Measles vaccine, regulation of interferon production, 1387
Measles virus, restriction of viral gene expression in measles inclusion body encephalitis, 144
Mediterranean spotted fever, treatment of retinal arterial occlusion, 1139
Melioidosis, biologic false-positive reactions in serological tests, 491
Meningitis
and bacteremia, due to *S. pneumoniae*, antimicrobial resistance of serogroups, 956
bacterial, acute, fever and disturbances in thermoregulation in adult patients, 496
coccidioidal, treatment with fluconazole, 903
due to *H. influenza* type b, in vaccinated children, 343
due to *L. monocytogenes*, and rhabdomyolysis and acute renal failure, 492
due to *S. pneumoniae* with a lytic defect, 36
tuberculous, diagnosed by ELISA, 681
Metronidazole, parenteral, failure of treatment for pseudomembranous colitis, 1146, 1147
Mezlocillin, bleeding associated with treatment, 669
Molluscum contagiosum
cryptococcal infection mimicking, 897
molecular epidemiology, 898
Monocytes, in AIDS, surface markers of function and activation, 483
Mumps, outbreak in postvaccine era, 1253
Murine leukemia virus, changes in hair of mice, 900
Mycobacterium smegmatis
disease in humans, treatment, 52
susceptibility to antimicrobial agents, 52
Mycobacterium tuberculosis
abdominal infection, clinical features, 687
antigen and antibody detection by ELISA, 681
detecting antibody and antigen to, 678
detection in culture by immunoassay, 468
HLA phenotype analyses, immune response, 1302
predictors of short-term prognosis in pulmonary disease, 366
Myelopathy, chronic progressive, HTLV-I in, 1193
Myositis, streptococcal, efficacy of clindamycin, erythromycin, and penicillin, 23

Nasal tolerance of intranasally administered rIFN-β_{ser}, 166
Neisseria gonorrhoeae
cervical infection, prophylaxis with nonoxynol-9, 518
serological reactivities of outer membrane proteins IA and IB, 529
Neisseria meningitidis
common epitopes of pilin, 332
group B
experimental meningitis, protective efficacy of monoclonal antibodies, 209
vaccination against, 710
Nephrotoxicity, influence of tobramycin dosage regimens in an experimental model, 13
Neutrophil chemotaxis, effects of granulocyte-macrophage colony-stimulating factor, 1140
Neutrophils
activation by *C. albicans*, role of guanosine triphosphate–binding proteins, 1056
impaired bactericidal capacity in AIDS, 627
stimulation by *C. trachomatis*, 457
Nocardia asteroides, causing actinomycetoma of the hand, 244
Nonoxynol-9, for preventing gonococcal and chlamydial infections, 518
Nosocomial infection
adenovirus, 3a, molecular epidemiology, 423
C. difficile, typed by plasmid profile, 731
C. krusei transmitted by lemon juice, 654
cryptosporidiosis in marrow transplant recipients, 647
L. pneumophila in cardiac transplant recipients, 651
varicella, 238

1,25 Dihydroxyvitamin D_3, effects on leukocytes in patients undergoing hemodialysis, 1102
Oocysts, *Cryptosporidium*, characteristics of typical and atypical forms, 1038
Ophthalmia neonatorum, due to *C. trachomatis*, 524
Ornithine decarboxylase, lack of detectable activity against *P. carinii*, 1137
Osteomyelitis, experimental, due to *P. aeruginosa*, aztreonam therapy, 660
Otitis media, due to *B. catarrhalis*, 205
Ototoxicity, influence of tobramycin dosage regimens in an experimental model, 13
Outer membrane proteins
IA and IB of *N. gonorrhoeae*, 529
of *B. catarrhalis*, comparison of 50 strains, 761
Oxacillin, acquired resistance in *S. aureus* strains, 702

Pancytopenia, prolonged, due to combined therapy with ganciclovir and zidovudine, 489
Parvovirus B19 infection, during pregnancy, 659
Pelvic inflammatory disease, acute, etiology and outcome, 510
Penicillin
bactericidal response of group A streptococci, 488
for treating experimental streptococcus myositis, 23
Penicillin G
detection of a slow-elimination phase, 200
pharmacokinetics in humans, 200
Penicillins, bleeding due to platelet dysfunction, 669
Peritonitis, due to *M. tuberculosis*, 687
Perspective
aminoglycoside dosing regimens, 1
endotoxin, protective antibody to, 286
immunodiagnosis of tuberculosis, 678
treatment of cerebral malaria, 320
Pertussis toxin, neutralizing antibodies to, 991
Phagocytosis, *L. monocytogenes*, by alveolar macrophages, 1309

Pharmacokinetic parameters, correlation with efficacy in an animal model, 831
Pili, of *N. meningitidis*, common epitopes, 332
Pipericillin, bleeding associated with treatment, 669
Plasmid profile typing of nosocomial *C. difficile*, 731
Plasmodium brasilianum, and EBV infection in marmosets, development of glomerulonephritis, 789
Plasmodium falciparum
  antibodies to sporozoites, immunity to, 868
  malaria
    and increased levels of interleukin-2 receptor, 1403
    treatment with quinine plus clindamycin, 1368
Platelet dysfunction, due to penicillins, causing bleeding, 669
Pneumocystis carinii
  cloning of DNA, 859
  glycoproteins, characterization, 1353
  lack of detectable activity of ornithine decarboxylase, 1137
  surface glycoproteins and purification and characterization of surface antigens, 848
Pneumonia
  associated with *C. trachomatis*, 524
  CMV, associated cytotoxic response, 773
  due to *C. burnetii*, 497
  due to group C *Streptococcus*, antibody response to group C carbohydrate, 1092
  due to *P. aeruginosa*, tobramycin treatment regimens, 7
  fatal measles, in child with AIDS, 480
Poliovirus, immune response to
  oral and inactivated vaccines, 160
  virion polypeptides after immunization, 160
Polymerase chain reaction, 1154, 1158
  characterization of HTLV-I sequence in chronic progressive myelopathy, 1193
  for detecting
    CMV DNA
      in blood, 1185
      in urine, 1177
    HIV DNA, 1170
Polymorphonuclear leukocytes
  effects of fibronectin on interaction with bacteria, 823
  impaired function in AIDS and ARC, 1268
Polysaccharides, sulfated, antiviral activity against HIV, 1084
Polyserositis, associated with Lassa fever, 872
Postantibiotic effect, in vitro and in vivo, of imipenem with or without gentamicin, in experimental pseudomonas endocarditis, 542
Prosthetic devices, bacterial colonization of, 203
Pseudomembranous colitis, failure of treatment with parenteral metronidazole, 1146, 1147
Pseudomonas aeruginosa
  absence of postantibiotic effect of imipenem in experimental endocarditis, 542
  aminoglycoside resistance to, in experimental endocarditis, 1003
  causing osteomyelitis, aztreonam therapy, 660
  experimental endocarditis, pharmacokinetics and pharmacodynamics of amikacin and ceftazidine, 355
  experimental pneumonia, tobramycin treatment regimens, 7
  mechanism(s) of ciprofloxacin resistance, 537
  monoclonal antibody to aminoglycoside-resistance factor, 1324
  scalp infection in neutropenic patients, 655
Pseudomonas pseudomallei, false-positive reactions in serological tests in melioidosis, 491
Pulmonary disease, chronic obstructive, changes in outer membrane proteins of nontypable *H. influenzae*, 360
Pyelonephritis
  acute, during long-term catheterization, 1341
  internalization of *E. coli* into renal tubular epithelial cells, 221

Q fever
  cross-reacting antibodies to *L. pneumophila* group 4, 499
  exposure to parturient cats as a risk factor, 101
  hepatitis in, 497
  pneumonia in, 497
  surveillance for, 497
Quinine, plus clindamycin, for treating *P. falciparum* malaria, 1368

Renal failure, acute, and rhabdomyolysis associated with listeria meningitis, 492
Renal transplantation
  and acute rotavirus gastroenteritis in an adult, 1400
  serological investigation of BK virus and JC virus infections, 176
  syphilitic hepatitis after, 236
Respiratory syncytial virus, infection
  effect of altitude and weather on occurrence, 1401
  in a cardiac transplant recipient, 650
Respiratory tract infection
  acute lower, in Filipino children, 1095
  CMV pneumonitis in marrow recipients, 488
Respiratory viruses, nosocomial outbreak of adenvirus 3a, 423
Retrovir®, prophylaxis for health care workers, 503
Retrovirus, detection by polymerase chain reaction, 1158
Rhabdomyolysis, and acute renal failure associated with listeria meningitis, 492
Rhinovirus
  experimental colds due to, prophylaxis with rIFN-β_{ser}, 166
  lack of fomite transmission, 888
Ribavirin
  aerosol dosage and deposition according to age, 443
  for treating RSV infections in cardiac transplant recipients, 650
Rickettsia rickettsii, cloned antigen as a vaccine for Rocky Mountain spotted fever, 228
Rickettsiae, spotted fever group, *See* Spotted fever group rickettsiae
Rocky Mountain spotted fever, experimental vaccine, 228
Rotavirus
  acute gastroenteritis due to, 1400
  antibodies in colostrum, breast milk, and maternal and cord blood, 477
  diarrhea due to, in the United States, 1112
  gastroenteritis, sequential outbreaks, 814
  human-rhesus reassortment, 1261
  infection
    serum and salivary antibody responses in neonates, 1117
    surveillance of morbidity and mortality, 1112
  lack of genomic reassortment between groups A and B in vivo, 1120
  protective effect of WC3 vaccine against diarrhea, 570
  reinfections, symptomatic and asymptomatic, with serotypes 1 and 3, 814
  seroconversion patterns in infants with acute gastroenteritis, 588

Rotaviruses, identification of groups by terminal fingerprint analysis, 657
Roxithromycin, for treating *I. belli* infection, 646
Rubella virus
  prenatal and postnatal production of IgM and IgA, 138
  quantitation of IgM and IgA by antibody-capture immunoassay, 138

Salmonella, vaccine strains harboring mutations in two *aro* genes, 1329
Salmonella dublin, plasmid-cured strain for immunization against group D and group B *Salmonella* infection, 460
Salmonella minnesota
  differential protective activity of IgM and IgG to Re mutant, 291
  immunization of mice and humans with Re mutant, 301
  Re mutant
    differential protective activity of IgM and IgG, 291
    immunization of volunteers and mice, 301
Salmonella typhi, treatment of typhoid fever by using ceftriaxone or chloramphenicol, 742
Salpingitis, due to *C. trachomatis*, 510
Scalp infections, hair clipping as a hazard for neutropenic patients, 655
Schistosoma mansoni
  eggs, endothelial cell proliferation, response to soluble egg antigen, 556
  neovascularization in, 556
Scrapie
  comparison of normal cellular and agent proteins, 1198
  protein purification, bioassay, 1198
Septic shock, gram-negative, *See* Gram-negative septic shock
Septicemia, *C. tertium*, in patients with neutropenia, 1336
Sequences. by polymerase chain reaction, 1158
Seroepidemiology, human T lymphotropic viruses and hepatitis viruses in prostitutes in Taiwan, 633
Serological reactivities of *N. gonorrhoeae* recombinant strains, 529
Serum sickness, reactions to cefaclor, 474
Shiga toxin, deletion of gene in *S. dysenteriae* type 1, 737
Shigella dysenteriae type 1
  isolates with deletion of Shiga toxin gene, 737
  role of Shiga toxin in virulence, 737
Shigella sonnei, infection, serum and fecal antibody responses to, 1108
Simian immunodeficiency virus infection, antibody response to, in rhesus monkeys, 1277
Sinusitis, due to *Cryptosporidium*, 649
Smoking, alveolar macrophages, phagocytosis and killing, 1309
Spotted fever group rickettsiae, isolation from humans in Japan, 663, 664
Staphylococci
  adherence to protein-coated surfaces, 693
  enterotoxin antibodies in children, 1105
Staphylococcus aureus
  impaired killing of neutrophils in AIDS, 627
  localization of an epitope on toxic-shock-syndrome toxin-1, 549
  treatment of infections due to oxacillin-resistant strains, 702
Streptococci, group A, *See* Group A streptococci
Streptococci, group B, *See* Group B streptococci
Streptococcus faecalis
  β-lactamase producing, causing serious infection, 1144
  infection, high-level resistance to gentamicin, 1144
Streptococcus pneumoniae
  AIDS vaccine, 983
  antibodies to pneumococcal polysaccharides, in children, 948
  antimicrobial resistance of serogroups causing bacteremia and meningitis, 956
  defective lysis in clinical strains, 36
  epidemiological studies in children, 948
Streptococcus pyogenes
  myositis, efficacy of clindamycin, erythromycin, and penicillin, 23
  restriction enzyme analysis of DNA, 1317
Syphilis
  causing hepatitis, in a renal transplant recipient, 236
  congenital charaterization of circulating immune complexes, 940
  incubating and early, treatment with ceftriaxone, 881

T cells, $CD8^+$ helper cell function in AIDS, 893
Tamm-Horsfall protein, effect on *E. coli* adherence, 1379
Ticarcillin, bleeding associated with treatment, 669
Tobramycin
  influence of dosage regimens on efficacy in an experimental model of subcutaneous abscess, 13
  resistance, to *P. aeruginosa*, mechanisms, 1003
  single daily vs intermittent dosing, for experimental *P. aeruginosa* pneumonia, 7
Toxic shock syndrome
  experimental
    detection of tumor necrosis factor, 1017
    induced by TSST-1, 1017
  serological and biologic analyses of TSST-1, 1287
  structural analysis of TSST-1, 1287
  tumor necrosis factor in, 1026
Toxic-shock-syndrome toxin-1
  effect of magnesium, 44
  S. aureus, localization of an epitope, 549
Toxins, cholera and *E. coli*, receptor blockade, 1147, 1148
Trachoma
  due to *C. trachomatis*, pathogenesis, 1347
  nonculture methods of diagnosis, 1347
Travelers' diarrhea, due to enteroinvasive *E. coli*, 640
Treponema pallidum
  causing hepatitis in a renal transplant recipient, 236
  infection, ceftriaxone therapy for, 881
Tribute
  Zhen-xiang Huang, 677
  Karel Raska, 915
  Wesley William Spink, 505
Trichosporon beigelii
  cross-reaction of cell wall with *C. neoformans* capsular polysaccharide, 901
  demonstration of cell wall antigen by immunoelectronmicroscopy, 901
Trypanosoma cruzi, infection, treatment with ketoconazole or itraconazole, 1408
Tuberculosis
  abdominal. clinical features, 687
  antibody and antigen detection, 678
  control and prevention, workshop report, 248
  HLA phenotypes and immune response, 1302
  immunodiagnosis of, 678

meningeal
diagnosis by ELISA, 681
in AIDS, adenosine deaminase activity as diagnostic test, 896
pulmonary, predictors of short-term prognosis, 366
rapid detection by immunoassay, 468
Tumor necrosis factor
induced by experimental toxic shock syndrome, 1017
produced by human monocytes, in response to TSST-1, 1026
Typhoid fever, treatment using ceftriaxone or chloramphenicol, 742

Urethritis, nongonococcal, clinical and microbiological features and antibiotic treatment in men, 1098
Urinary tract infection
asymptomatic, in elderly women, 494
bacterial attachment induced by inflammation, 29
caused by *E. coli*, in boys, 996
P fimbriae in, 495

Vaccine
B subunit–whole cell cholera, cross-protection against enterotoxigenic *E. coli*, 372
capsular polysaccharide
S. pneumoniae, antibody response in HIV infection, 983
H. influenzae type b, isotype distribution of antibodies, 973
dengue virus type 3, trial, 876
E. coli O111:B4, antibody response in human volunteers, 1135
experimental, Rocky Mountain spotted fever, 228
genetically engineered HSV, evaluation in rodents, 602
H. influenzae, disease in vaccinated children, 343
H. influenzae type b
conjugate, responses and isotype distribution of antibodies, 973
PRP-pertussis and PRP-D conjugate, immune response to, 719
influenza A, comparison of live and inactivated influenza in adults, 1209
live attenuated varicella, immunization of adults, 132
measles, regulation of interferon production, 1387
meningococcal serotype protein, response to, 710
mumps, efficacy during an outbreak, 1253
oral cholera, field trial in Bangladesh, 60
plasmid-cured strain of *S. dublin*, against group D and group B *Salmonella* infection, 460
poliovirus, immune response to, 160
rotavirus
human-rhesus reassortment, 1261
safety and immunogenicity, 1261
S. pneumoniae, for AIDS, 983
salmonella, oral, 1329
temperature-sensitive mutants of mouse CMV, in mice, 596
varicella, immunity to viral proteins, 1245
WC3, protection against rotavirus diarrhea, 570
Vaccinia viruses, recombinant, expressing HSV-1 glycoproteins B and D, protection against acute and latent HSV infection, 1382
Vancomycin
adverse effects, 1413
for treating serious infection due to β-lactamase–producing *S. faecalis*, 1144
intraventricular, for CSF shunt infections, 1142
pharmacokinetics, in CSF, 1142
Varicella, mimicking a vesiculobullous sun eruption, 243
Varicelia-zoster virus
airborne transmission from localized zoster, 238
HLA-restricted cytotoxicity, 780
immunity to viral proteins, 1245
infection after liver transplantation, effect on OKT3 antibodies, 124
live attenuated vaccine in adults, 132
vaccine-induced immunity, 1245
Viral infections, latent, in bone marrow transplant recipients, 563

Whooping cough, assay of neutralizing antibodies to pertussis toxin, 991
Workshop report, control and prevention of tuberculosis, 248

Yeasts, adherence of *Candida* spp. enhanced by bioemulsifer, 636

Zidovudine
combined with ansamycin, for in vitro HIV infection, 895
combined with ganciclovir, causing prolonged pancytopenia, 489
rebound of HIV antigen after discontinuing therapy, 1132
restricted transport through the blood-brain barrier, in rats, 630
Zidovudine, *See also* Retrovir